Analysts' Ratings and Earnings for Ariad Pharmaceutical

Lookup Another Company: :

Quick Links: Consensus Ratings, Ratings History, Earnings History, Company Description

Consensus Ratings for Ariad Pharmaceutical (NASDAQ:ARIA) (?)

Ratings Breakdown:	2 Hold Rating(s), 14 Buy Rating(s)
Consensus Rating:	Buy
Consensus Price Target:	$28.21 (53.09% upside)

Analysts' Ratings History for Ariad Pharmaceutical (NASDAQ:ARIA)

Date	Firm	Action	Company	Old Rating	New Rating	Old Price Target	New Price Target	Details
5/22/2013	RBC Capital	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Outperform		$36.00	View
4/12/2013	Jefferies Group	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy		$25.00	View
4/1/2013	Jefferies Group	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy		$25.00	View
3/28/2013	Goldman Sachs	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Neutral			View
3/20/2013	Bank of America	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy	$26.00	$27.00	View
2/27/2013	William Blair	Lower Price Target	Ariad Pharmaceutical (ARIA)			$28.00	$27.00	View
2/26/2013	Jefferies Group	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$23.00	$25.00	View
2/26/2013	Barclays Capital	Lower Price Target	Ariad Pharmaceutical (ARIA)		Overweight	$30.00	$29.00	View
2/14/2013	Stifel Nicolaus	Lower Price Target	Ariad Pharmaceutical (ARIA)		Buy	$27.00	$26.00	View
2/8/2013	JMP Securities	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Outperform			View
1/16/2013	RBC Capital	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Outperform			View
1/8/2013	Brean Murray	Lower Price Target	Ariad Pharmaceutical (ARIA)		Buy	$35.00	$29.00	View
1/3/2013	UBS AG	Lower Price Target	Ariad Pharmaceutical (ARIA)		Buy	$29.00	$26.00	View
12/17/2012	Barclays Capital	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Overweight		$30.00	View
12/17/2012	Maxim Group	Lower Price Target	Ariad Pharmaceutical (ARIA)				$24.00	View
12/17/2012	Jefferies Group	Set Price Target	Ariad Pharmaceutical (ARIA)		Buy	$27.00	$23.00	View
12/17/2012	William Blair	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Outperform		$28.00	View
12/14/2012	Cowen Securities	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Outperform			View
12/14/2012	Citigroup	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy		$31.00	View
12/7/2012	Dawson James	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Outperform		$32.00	View
11/9/2012	Guggenheim	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Buy			View
10/25/2012	Citigroup	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Buy		$31.00	View
10/23/2012	Oppenheimer	Downgrade	Ariad Pharmaceutical (ARIA)	Outperform	Perform	$20.00	$23.00	View
10/22/2012	Jefferies Group	Lower Price Target	Ariad Pharmaceutical (ARIA)		Buy	$28.00	$27.00	View
10/2/2012	UBS AG	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy			View
10/2/2012	Jefferies Group	Reiterated Rating	Ariad Pharmaceutical (ARIA)	Buy	Buy		$28.00	View
10/1/2012	Bank of America	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$26.00	$30.00	View
10/1/2012	Maxim Group	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy		$28.00	View
10/1/2012	Summer Street	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$21.00	$34.00	View
10/1/2012	Brean Murray	Boost Price Target	Ariad Pharmaceutical (ARIA)	Buy	Buy	$19.00	$35.00	View
9/21/2012	RBC Capital	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Outperform			View
9/18/2012	Maxim Group	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$24.00	$28.00	View
9/10/2012	Bank of America	Upgrade	Ariad Pharmaceutical (ARIA)	Neutral	Buy	$20.00	$26.00	View
9/6/2012	Stifel Nicolaus	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$20.00	$24.00	View
7/31/2012	Rodman & Renshaw	Boost Price Target	Ariad Pharmaceutical (ARIA)		Outperform	$22.00	$26.00	View
7/30/2012	William Blair	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Outperform		$25.00	View
7/18/2012	Oppenheimer	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Outperform			View
6/6/2012	Jefferies Group	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy (N/A)			View
6/5/2012	Barclays Capital	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Overweight			View
5/14/2012	Summer Street	Boost Price Target	Ariad Pharmaceutical (ARIA)				$21.00	View
5/14/2012	Summer Street	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$16.00	$21.00	View
5/10/2012	Jefferies Group	Boost Price Target	Ariad Pharmaceutical (ARIA)				$18.00	View
4/12/2012	UBS AG	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Buy	$20.00	$20.00	View
3/21/2012	Stifel Nicolaus	Lower Price Target	Ariad Pharmaceutical (ARIA)				$18.00	View
3/15/2012	Stifel Nicolaus	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Buy		$19.00	View
2/29/2012	Oppenheimer	Boost Price Target	Ariad Pharmaceutical (ARIA)				$20.00	View
2/28/2012	Rodman & Renshaw	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Market Perform		$18.00	View
2/13/2012	RBC Capital	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Outperform		$20.00	View
1/19/2012	Maxim Group	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Buy		$20.00	View
1/11/2012	Rodman & Renshaw	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Outperform		$18.00	View
12/27/2011	Rodman & Renshaw	Boost Price Target	Ariad Pharmaceutical (ARIA)		Market Perform	$15.00	$18.00	View
12/12/2011	Bank of America	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Neutral		$14.00	View
12/12/2011	JPMorgan Chase	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Overweight			View
12/12/2011	Jefferies Group	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy			View
12/9/2011	Barclays Capital	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Overweight		$19.00	View
12/2/2011	Jefferies Group	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Buy		$16.00	View
11/17/2011	Zacks	Upgrade	Ariad Pharmaceutical (ARIA)	Underperform	Neutral			View
11/15/2011	Goldman Sachs	Upgrade	Ariad Pharmaceutical (ARIA)	Hold	Neutral			View
11/1/2011	Rodman & Renshaw	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Outperform		$15.00	View
10/14/2011	Rodman & Renshaw	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Outperform		$15.00	View
10/5/2011	Zacks	Downgrade	Ariad Pharmaceutical (ARIA)	Neutral	Underperform			View
9/26/2011	Bank of America	Reiterated Rating	Ariad Pharmaceutical (ARIA)		Neutral		$14.00	View
9/14/2011	Oppenheimer	Boost Price Target	Ariad Pharmaceutical (ARIA)			$16.00	$17.00	View
8/2/2011	Brean Murray	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$11.00	$15.00	View
6/20/2011	Oppenheimer	Boost Price Target	Ariad Pharmaceutical (ARIA)			$11.00	$13.00	View
5/25/2011	Brean Murray	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Buy	$9.00	$11.00	View
4/28/2011	Zacks	Reiterated Rating	Ariad Pharmaceutical (ARIA)	Neutral	Neutral			View
3/24/2011	Williams Capital	Initiated Coverage	Ariad Pharmaceutical (ARIA)		Outperform		$10.00	View
1/19/2011	Brean Murray	Boost Price Target	Ariad Pharmaceutical (ARIA)		Buy	$5.00	$9.00	View

Click Here to view only the most recent ratings from each analyst for this stock.

Earnings History for Ariad Pharmaceutical (NASDAQ:ARIA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2013	Q1 2013	($0.38)	($0.36)	$5.01 million	$6.40 million	View Release	Listen to Call
2/25/2013	Q4 2012	($0.36)	($0.36)	$78.00 million	$0.07 million	View Release	Listen to Call
11/7/2012	Q312	($0.32)	($0.32)	$0.96 million	$0.85 million	View Release	N/A
8/2/2012		($0.27)	($0.31)			View Release	N/A
5/9/2012		($0.23)	($0.35)			View Release	N/A
2/28/2012		($0.20)	($0.38)			View Release	N/A
11/3/2011		$0.02	$0.10			View Release	N/A
8/2/2011		($0.16)	($0.36)			View Release	N/A
5/5/2011		($0.13)	($0.29)			View Release	N/A
2/17/2011		($0.14)	($0.25)			View Release	N/A

About Ariad Pharmaceutical

ARIAD Pharmaceuticals, Inc. (ARIAD) is biopharmaceutical company. As of December 31, 2011, the Company's pipeline contains three product candidates: ponatinib, AP26113 and ridaforolimus. It is building a pipeline of product candidates that expand upon treatment options for patients with cancer. Each of its product candidates were discovered internally. It is building a commercial organization to market, distribute and sell its products upon regulatory approval in the United States, Europe and other select markets, worldwide. It has commenced preparations for the commercial launch of ponatinib in the United States and Europe.